To understand the status of oropharyngeal yeast colonization in human immunodeficiency virus (HIV) -infected outpatients in the era of highly active antiretroviral therapy (HAART), we conducted a prospective, cross-sectional study from October 2009 to January 2010 at a medical centre in southern Taiwan. Fungal cultures of the oropharyngeal swabs were performed on 327 enrolled patients.
Introduction
Oropharyngeal colonization by Candida species in human immunodeficiency virus (HIV) -infected patients [1] [2] [3] [4] may evolve to oro-oesophageal candidiasis during progressive immunodeficiency [5] , which can subsequently hamper the nutritional intake of patients and increase the medical cost of patient management. In HIV-infected patients, Candida albicans is the main species of colonization [3, 6] . However, colonization by C. dubliniensis has increased in recent years [3, 7, 8] . Oral candidiasis usually responds to effective antifungal agents, but the antifungal susceptibility profile varies with Candida species and previous use of antifungal agents [9] .
In Taiwan, the overall prevalence of HIV infections increased from 0.16& in 2001 to 0.89& in 2010 [10] . The government has been providing free highly active antiretroviral therapy (HAART) to HIV-infected patients in Taiwan since 1997. Consequently, the number of patients receiving HAART has increased in the recent decade. Although the risk factors and species distribution of oropharyngeal yeast colonization in HIV-infected patients had been discussed in our previous studies conducted in 1999-2002 and 2005 [1, 6] , the effect of different antiretroviral agents on colonization was not addressed. Moreover, there was a dramatic increase in the population of HIV-infected intravenous drug users (IDUs) between 2004 and 2006 in Taiwan [11] . Facing a changing epidemiology, we conducted another survey between 2009 and 2010 to investigate the risk factors and species distribution of oropharyngeal yeast colonization in HIV-infected patients and the antifungal susceptibility of isolates recovered from the survey, with the hope of providing useful information to assist the population.
Materials and Methods

Study population and data collection
This prospective cross-sectional study was conducted from October 2009 to January 2010. The study was approved by the Human Experiment and Ethics Committee of National Chen-Kung University Hospital, a medical centre in southern Taiwan. HIV-infected patients at the outpatient infectious diseases clinic were enrolled after informed consents had been obtained. A standardized data collection form was used to retrieve demographic characteristics (age, gender and types of HIV transmission), known period of HIV infection, the underlying medical conditions, and information within the 6 months prior to enrolment, including the presence of oral thrush, the latest CD4 cell counts and HIV viral loads, history of hospitalization and residence in jails or rehabilitation centres, and recent receiving of antibacterial/antifungal treatments for ‡ 1 day, and antiretroviral agents for ‡ 2 weeks within 3 months of enrolment.
Sample collection and fungal cultures
Oropharyngeal swabs were obtained using a dry sponge swab (EZ Culturette; Becton Dickinson, Sparks, MD). All swabs were maintained at room temperature and transported to the central laboratory at the National Health Research Institutes within 24 h. The swabs were then streaked onto Chromagar Candida agar medium (CHROMagar, Paris, France). All plates were incubated at 30°C. Three, if present, colonies from each plate were selected for further analyses. Additional colonies were selected from the plates when there was more than one morphotype present. All isolates were subjected to the VITEK Yeast Biochemical Card (bioMérieux; Marcy l'Etoile, France) for species identification. When the Yeast Biochemical Card identification probability was less than 90% or when uncommon species were reported, the sequences of the internal transcribed spacer (ITS) region and the D1/D2 region of ribosomal DNA were used for species identification. The ITS regions were amplified using the primers ITS1, 5¢-TCCGTAGGTGAACCT GCGG-3¢ and ITS4 5¢-TCCTCCGCTTATTGATATGC-3¢, and the D1/D2 regions were amplified using the primers NL1 5¢-GCATATCAATAAGCGGAGGAAAAG-3¢ and NL4 5¢-GGTCCGTGTTTCAAGACGG-3¢ [12, 13] .
Antifungal susceptibility tests
The MICs of antifungal drugs were determined according to the guidelines of M27-A3 recommended by the Clinical and Laboratory Standards Institute [14] . The RPMI-1640 medium (31800-022, Gibco BRL, Carlsbad, CA) was used for the dilution and growth of the yeast culture. Strains from American Type Culture Collection (ATCC, Manassass, VA), including C. albicans (ATCC 90028), C. krusei (ATCC 6258) and C. parapsilosis (ATCC 22019), were used as the standard controls. Growth of each isolate was measured by the Biotrak II plate spectrophotometric reader (Amersham Biosciences, Biochrom Ltd., Cambridge, UK) after incubation at 35°C for 48 h.
The MICs for amphotericin B and azoles were defined as the lowest concentrations capable of preventing any discernible growth and of reducing the turbidity of cells by >50%, respectively. For amphotericin B, MICs of ‡2 lg/mL were considered resistant and £1 lg/mL susceptible. For fluconazole, MICs of ‡64 lg/mL were considered resistant and £8 lg/mL susceptible. The isolates with MICs in the range of 16-32 lg/mL were referred to as susceptible-dose-dependent. For voriconazole, MICs of ‡4 lg/mL were considered resistant and £1 lg/mL susceptible [14] . Generally, only one isolate of each patient was analysed. Nevertheless, when a patient was colonized by more than one species, one isolate of each species was included.
Statistical methods
The results were analysed with SPSS software for Windows, version 12.0. Variables collected in the data collection form were tested for association with yeast colonization and infection. The chi-square test was applied for categorical variables, and the Student's t-test for continuous variables. Logistic regression was applied to assess the independent effects of factors found to be significant in the univariate analysis. A p value <0.05 was considered significant.
Results
Patients
During the study period, a total of 327 patients were enrolled. Their demographic data are shown in Table 1 . They were predominantly men (299, 91.4%) and 36 (11%) patients were IDUs. Overall, 42 (12.8%), 73 (22.3%) and 212 (64.8%) patients had a CD4 cell count £200, 201-350 and >350 cells/mm 3 , respectively. At enrolment, 258 (79%) patients were receiving HARRT.
Status and risk factors for yeast colonization
Of the 327 patients, 193 (59%) were colonized by yeasts, among whom 157 (81.3%), 25 (13.0%) and 11 (5.7%) were by single, two and more than two species, respectively. A higher proportion of patients with low CD4 cell counts were colonized by yeasts than those with higher counts (81% in £200/mm 3 versus 56% in >200/mm 3 , p 0.002). By univariate analysis, patients who were IDUs, patients who had been exposed to antibacterial agents, and patients who received mycostatin oral suspension in the previous 6 months were at risk for colonization, whereas a CD4 cell count >200 cells/ mm 3 and being in receipt of lamivudine or lamivudine/zidovudine, or efavirenz protected patients from colonization. Use of protease inhibitors (atazanavir or lopinavir/ritonavir) had no significant effect on colonization (p 0.26). By multivariate analysis, receipt of efavirenz and a CD4 count >200 cells/ mm 3 protected patients from colonization, whereas IDUs were at risk for colonization (Table 1) . Furthermore, the protective effect of efavirenz-based antiretroviral therapy on 
Species distribution and antifungal susceptibility of yeasts
Of the 241 yeast isolates characterized, 12 isolates needed to be speciated by DNA sequencing of the ribosomal DNA fragments. Seven isolates, including three C. glabrata, two C. albicans, one C. guilliermondii and one C. membranifaciens, were identified by sequencing the ITS fragments and four isolates, including one each of C. glabrata, C. inconspicua, C. membranifaciens and C. tropicalis, were identified by sequencing the D1/D2 fragments. The remaining isolate, Metschnikowia spp., could not be identified to species level even using both ITS and D1/D2 sequence. The colonization species were C. albicans (168, 69.7%), C. dubliniensis (23, 9.5%), C. glabrata (20, 8 .3%), C. tropicalis (8, 3.3%), C. intermedia (5, 2.1%), C. parapsilosis (4, 1.7%) and Saccharomyces cerevisiae (3, 1.2%), and others (10, 4.0%) ( Table 2) . Overall, Candida species accounted for 97.5% of these isolates. All 15 patients with previous or current oral thrush were colonized by C. albicans at enrolment, and two were simultaneously colonized by C. tropicalis, one by C. dubliniensis and one by C. glabrata. Patients with C. albicans colonization were significantly younger than those with non-C. albicans yeasts (39.6 versus 43.6 years, p 0.037). Risk factors for C. dubliniensis colonization were not identified. Furthermore, patients colonized with multiple species were associated with a longer known period of HIV infection (4.6 versus 3.5 years, p 0.011) and prior exposure to penicillin derivatives (OR, 9.0; 95% CI 1.28-63.92; p 0.027).
Of the 241 isolates, 230 (95.4%), 236 (97.9%) and 240 (99.6%) isolates were susceptible to fluconazole, voriconazole and amphotericin B, respectively (Table 2) . Seven (2.4%) and five (2.1%) isolates, mostly C. albicans (four and three isolates), were resistant to fluconazole and voriconazole, respectively. Eight Candida isolates, including six C. albicans isolates, one C. dubliniensis and one C. glabrata, were recovered from six patients who had received fluconazole for oral thrush. Of these eight isolates, only the C. glabrata isolate had increased MICs of fluconazole (8 lg/mL) and voriconazole (0.25 lg/mL) whereas the other seven isolates remained susceptible to fluconazole (MIC £1 lg/mL) and voriconazole (£0.03 lg/mL), irrespective of previous fluconazole exposure.
Discussion
The demographic and microbiological characteristics of oropharyngeal yeast colonization in HIV-infected and non-HIVinfected populations in our previous reports [1, 6, 15] [6] and 70% in the present study were C. albicans. Hence, the prevalence of non-albicans Candida species has indeed increased in the past decade. Clinical information about the effects of different antiretroviral agents on the risk of oropharyngeal yeast colonization or infection is limited. In 2000, HIV protease inhibitors were the first to be associated with a lower rate of oropharyngeal Candida colonization and candidiasis [16] . The positive impact of protease inhibitors has been attributed to a better immunological function with their use, or with their antifungal activity resulting from the similar structure of Candidasecreted aspartic protease with the targeted protein, i.e. HIV aspartic protease [17] . However, such an effect of protease inhibitors was not found in the present study as well as in another recent study [2] . Instead we found that receipt of an efavirenz-containing regimen was significantly associated with a lower frequency of oropharyngeal yeast colonization both in all enrolled patients and in patients receiving HAART. This is the first study showing the potential effect of efavirenz on oropharyngeal yeast colonization. Despite the statistical significance of efavirenz on reduced colonization, further clinical investigations involving more patients to determine the impact of the drug on colonization and in vitro antifungal activity are warranted.
In our previous study conducted in 2005 [1] , we found that all six IDUs were colonized by yeasts and had a CD4 count of >450 cells/mm 3 . This observation suggested that
IDUs may be at risk for yeast colonization. In the present study, we were able to reach a statistically significant association between IDU and yeast colonization. An earlier report had a similar finding, showing a higher prevalence of Candida lesions and oral yeast colonization among the HIV-infected IDU group than the HIV-infected heterosexual and homosexual groups [18] . Furthermore, studies showed that IDUs, regardless of their HIV serostatus, were more likely than homosexual men to present with oral candidiasis [19] [20] [21] . Several factors of the lifestyle, access to health care, and the hygiene conditions of the oral cavity before HIV infection, influenced the development of oral lesions in HIV-infected populations [20] . Whether those same factors contribute to oropharyngeal yeast colonization needs to be examined. Candida albicans was the major species, accounting for 70% of all yeast isolates colonizing the oropharynx of HIVinfected patients, a finding similar to previous studies in which C. albicans accounted for 60-83% of colonized isolates [3, 22, 23] , although a decreased isolation rate was found compared with that (87%) of our earlier study during 1999-2002 [6] . Another shift of species distribution in our studies was noted in C. dubliniensis, which was not recovered during 1999-2002 [6] but was increasingly detected in 2005 (4.3%) [1] and in the present study (9.5%). Little is known about the risk factors for C. dubliniensis colonization in HIV-infected patients, except for a higher prevalence in individuals of European descent (9%) compared with individuals of African descent (1.5%) in South Africans [24] . Neither did our study identify the risk factors for C. dubliniensis colonization. The clinical implication of these findings remains to be elucidated.
In conclusion, compared with our previous studies, CD4 cell counts £200 cells/mm 3 remained as a risk factor for oropharyngeal yeast colonization in HIV-infected patients, whereas non-receipt of efavirenz-based combinations and IDU were first identified as another two risk factors in the present study. The mechanism contributing to the effect of efavirenz on oropharyngeal yeast colonization needs further investigation. An increasing proportion of colonization by C. dubliniensis was also observed during the decade. Three tested antifungal agents, fluconazole, voriconazole and amphotericin B, remained effective against >95% of the colonized yeasts.
